Specialized Expertise in the Diagnosis & Treatment of Multiple Myeloma
Multiple myeloma is a cancer of the plasma cells in the bone marrow. When these plasma cells grow out of control and form bone tumors, they can cause pain and destruction of the bones, and make it more difficult for the bone marrow to make red blood cells, white blood cells and platelets. Multiple myeloma mainly affects older adults, and the American Cancer Society estimates that over 20,000 new cases are diagnosed in the U.S. annually.
The Multiple Myeloma Program at the Maimonides Cancer Center offers specialized expertise in the diagnosis and treatment of plasma cell disorders, including Monoclonal Gammopathy of Unknown Significance (MGUS), multiple myeloma, and primary amyloidosis. Our myeloma team consists of experts in hematology/oncology, radiation oncology, pain and palliative care, hematopathology, interventional radiology, orthopedics, nursing and social services.
Our multidisciplinary group formulates prospective diagnostic and therapeutic plans tailored to each person's illness, including its physical, emotional and social effects. Armed with a specific therapeutic plan, each patient has the total support of the myeloma team, as well as the ready availability of multiple social services, including a multiple myeloma support group, aide in obtaining insurance and financial support for medicines and other services.
The Maimonides Multiple Myeloma Program participates in clinical trials, including the personalized medicine initiative of the Multiple Myeloma Research Foundation (MMRF) the CoMMpass trial. Patients have access to established treatments such as IMIDs and proteosome inhibitors, as well as newer treatments through our clinical trials program. Our patients have access to stem cell transplant programs through a collaboration with Montefiore Medical Center/Albert Einstein School of Medicine.